CBER Director Marks’ Intervention On Sarepta Gene Therapy Filing Decision Appears To Backfire

 
• By Derrick Gingery
backfire
Stakeholders likely will closely watch the upcoming FDA advisory committee meeting on Sarepta's DMD gene therapy candidate. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies